The incidence of isolated hypophysitis due to anti‐PD1/PDL1 monotherapy was 5.5% (7/127) vs 4.2% (5/120) due to anti‐CTLA4 monotherapy and 9.8% (9/92) due to sequential and/or combination therapy with both anti‐CTLA4 and anti‐PD1 (Table 1). Here, CTLA4 is linked to hypophysitis.